4:16 PM
 | 
Dec 21, 2017
 |  BC Week In Review  |  Company News  |  Deals

Confo in GPCRs deals with Roche, Lundbeck

Confo Therapeutics N.V. (Brussels, Belgium) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to its small molecule agonists against an undisclosed GPCR.

Confo will receive a total of €6 million ($7.1 million) over 30 months, including an upfront payment, preclinical milestones and R&D funding. The biotech is also...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >